Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats

Biochemical and Biophysical Research Communications

Volumn 316, Issue 1, 2004, Pages 114-122

  Ko, Seung Hyun ^a   Kwon, Hyuk Sang ^a   Kim, Sung Rae ^a   Moon, Sung Dae ^a   Ahn, Yu Bae ^a   Song, Ki Ho ^a   Son, Hyun Sik ^a   Cha, Bong Yun ^a   Lee, Kwang Woo ^a   Son, Ho Young ^a   Kang, Sung Koo ^a   Park, Chung Gyu ^b   Lee, In Kyu ^c   Yoon, Kun Ho ^a  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Smooth muscle actin; Islet fibrosis; Otsuka Long Evans Tokushima fatty rat; Ramipril; Transforming growth factor

Indexed keywords

RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; EVALUATION; FIBROSIS; GENE EXPRESSION; GLUCOSE TOLERANCE; MALE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WEIGHT GAIN; WESTERN BLOTTING;

ACTINS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FIBROSIS; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; RAMIPRIL; RATS; RATS, INBRED OLETF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 10744229027     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.02.023     Document Type: Article

References (34)

1. Sidorov J., Shull R., Tomcavage J., Girolami S., Lawton N., Harris R. Does diabetes disease management save money and improve outcomes?: a report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care. 25:2002;684-689.
2. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Eng. J. Med. 34:2000;145-153.
3. L.H. Lindholm, H. Ibsen, B. Dahlof, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J. Edelman, S. Snapinn, LIFE study group, cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet 23 359 (9311) (2002) 1004-1010.
4. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H.R., Zinman B. HOPE study investigators, ramipril and the development of diabetes. JAMA. 286:2001;1882-1885.
5. Kawano K., Hirashima T., Mori S., Natori T. OLETF (Otsuka Long-Evans Tokushima fatty) rat: a new NIDDM rat strain. Diabetes Res. Clin. Pract. 24:1994;S317-S320.
6. Yoshikawa H., Kihara Y., Taguchi M., Yamaguchi T., Nakamura H., Otsuki M. Role of TGF-β1 in the development of pancreatic fibrosis in Otsuka Long-Evans Tokushima fatty rats. Am. J. Physiol. Gastrointest. Liver Physiol. 282:2002;G549-G558.
7. Clark A., Wells C.A., Buley I.D., Cruickshank J.K., Vanhegan R.I., Matthews D.R., Cooper G.J., Holman R.R., Turner R.C. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas of type 2 diabetes. Diabetes Res. 9:1988;151-159.
8. Yoon K.H., Ko S.H., Cho J.H., Lee J.M., Ahn Y.B., Song K.H., Yoo S.J., Kang M.I., Cha B.Y., Lee K.W., Son H.Y., Kang S.K., Kim H.S., Lee I.K., Bonner-Weir S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 88:2003;2008-2300.
9. Haber P.S., Keogh G.W., Apte M.V., Moran C.S., Stewart N.L., Crawford D.H., Pirola R.C., McCaughan G.W., Ramm G.A., Wilson J.S. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am. J. Pathol. 155:1999;1087-1095.
10. Yokuyasu T., Denham W., Murayama K., Pelham C., Joehl R., Bell R.H. Pancreatic stellate cell activation and MMP production in experimental pancreatic fibrosis. J. Surg. Res. 104:2002;106-111.
11. Leung P.S., Chan W.P., Wong T.P., Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J. Endocrinol. 160:1999;13-19.
12. Carlsson P.O. The renin-angiotensin system in the endocrine pancreas. J. Pancreas. 2:2001;26-32.
13. Leung P.S., Carlsson P.O. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J. Mol. Endocrinol. 26:2001;155-164.
14. Tahmasebi M., Puddefoot J.R., Inwang E.R., Vinson G.P. The tissue renin-angiotensin system in human pancreas. J. Endocrinol. 161:1999;317-322.
15. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio heart study. Diabetes Care. 20:1997;1087-1092.
16. Kanauchi M., Nakajima M., Saito Y., Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism. 52:2003;476-481.
17. Masson P. Trichrome stainings and their preliminary technique. J. Tech. Methods. 2:1929;75-90.
18. Pimentel J.J., Sundell C.L., Wang S., Kopp J.B., Montero A., Martinez M.M. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int. 48:1995;1233-1246.
19. Weibel E.R. Stereologic methods. Practical Methods for Biologic Morphometry. vol. 1:1978;101-161 Academic Press, London.
20. Bonner-Weir S. β-cell turnover: its assessment and implications. Diabetes. 50(suppl. 1):2001;S20-S24.
21. Uehara M., Kishikawa H., Isami S., Kisanuki K., Ohkubo Y., Miyamura N., Miyata T., Yano T., Shichiri M. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia. 37:1994;300-307.
22. Torlone E., Rambotti A.M., Periello G., Botta G., Santeusanio F., Brunetti P., Bolli G.B. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia. 34:1991;119-125.
23. Mehta A.A., Patel S., Santani D.D., Goyal R.K. Effect of nifedipine and enalapril on insulin-induced glucose disposal in spontaneous hypertensive and diabetic rats. Clin. Exp. Hypertension. 21:1999;51-59.
24. Carlsson P.O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 41:1998;127-133.
25. Leung P.S., Chan H.C., Fu L.X.M., Wong P.Y.D. Localization of angiotensin II receptor subtype AT1 and AT2 in the pancreas of rodents. J. Endocrinol. 153:1997;269-274.
26. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. Collaborative study group, the effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462.
27. Wolf G., Mueller E., Stahl R.A.K., Ziyadeh F.N. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β J. Clin. Invest. 92:1993;1372-1377.
28. van Laethem J.L., Deviere J., Resibois A., Rickaert F., Vertongen P., Ohtani H., Cremer M., Miyazono K., Robberecht P. Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology. 108:1995;1873-1881.
29. Menke A., Yamaguchi H., Gress T.M., Adler G. Extracellular matrix is reduced by inhibition of transforming growth factor beta1 in pancreatitis in the rat. Gastroenterology. 113:1997;295-303.
30. Kihara Y., Tashiro M., Nakamura H., Yamaguchi T., Yoshikawa H., Otsuki M. Role of TGF-beta1, extracellular matrix, and matrix metalloproteinase in the healing process of the pancreas after induction of acute necrotizing pancreatitis using arginine in rats. Pancreas. 23:2001;288-295.
31. Igarashi A., Okochi H., Bradham D.M., Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell. 4:1993;637-645.
32. Apte M.V., Haber P.S., Darby S.J., Rodgers S.C., McCaughan G.W., Korsten M.A., Pirola R.C., Wilson J.S. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 44:1999;534-541.
33. Shek F.W., Benyon R.C., Walker F.M., McCrudden P.R., Pender S.L., Williams E.J., Johnson P.A., Johnson C.D., Bateman A.C., Fine D.R., Iredale J.P. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 160:2002;1787-1798.
34. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277(1 Pt 1):1999;C1-C9.